AI-based cfDNA fragmentome liquid biopsy can detect early liver fibrosis, cirrhosis, and indicate broader chronic disease signals.
Key Details
- 1Johns Hopkins team applied AI and genome-wide cfDNA fragmentation analysis to diagnose early liver fibrosis and cirrhosis.
- 2Study analyzed samples from 1,576 people with liver disease and comorbidities using whole-genome sequencing.
- 3AI algorithms identified disease-specific fragmentation patterns, enabling high sensitivity detection of early liver disease.
- 4Current clinical tests often miss early fibrosis and only detect cirrhosis around 50% of the time.
- 5Prototype assay also signaled risk for other chronic diseases, such as cardiovascular and inflammatory conditions.
- 6Technology builds upon earlier cancer fragmentome studies, focusing now on non-cancer chronic conditions.
Why It Matters
Early detection of liver fibrosis is critical because it is reversible at early stages, potentially preventing progression to cirrhosis and cancer. This AI-enabled cfDNA approach could expand the role of noninvasive liquid biopsy in radiological diagnostics and broader chronic disease management.
Source
EurekAlert
Related News
•EurekAlert
AI Tool Predicts Financial Toxicity Risk in Cancer Patients
Researchers developed a machine learning model to proactively identify cancer patients at high risk of financial stress from treatment.
•EurekAlert
Researchers Develop All-Optical Synapse for Neuromorphic Imaging Systems
A new artificial synapse, controlled entirely by light, enables in-sensor neuromorphic processing for more efficient and noise-resistant imaging systems.
•EurekAlert
Mayo Clinic Showcases Imaging AI and Early Cancer Detection Advances at ASCO 2026
Mayo Clinic researchers will present over 30 studies at ASCO 2026, highlighting new advances in imaging AI, data science, and early cancer detection.